Addendum
Fluticasone furoate/umeclidinium/vilanterol (COPD) - Addendum to Commission A18-79
Report documents
-
Addendum
Fluticasone furoate/umeclidinium/vilanterol (COPD) - Addendum to Commission A18-79
Dossier assessment
Indication:
Maintenance treatment in adults with moderate to severe COPD who still have symptoms under a combination of a LABA and a LAMA
Result of dossier assessment:
Additional analysis of a comparison with a treatment that is not in line with the appropriate comparator therapy; assessment result of A18-79 unchanged
Additional information
Federal Joint Committee (G-BA)
2019-05-02 A G-BA decision was published.
Project details
- Project no.
- A19-27
- Commission
- Commission awarded on 26.03.2019 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Airways and respiratory system
- Note
-
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
Connected Projects
-
Dossier assessment
Fluticasone furoate/umeclidinium/vilanterol (COPD) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed